Agitation,Psychomotor Clinical Trial
Official title:
Agitation Follow up After Introduction of a New Patient Care Algorithm
Agitation in the intensive care unit is motor hyperactivity. It is frequent (b/w 30% to 70%) and has multiple causes: pain, medical reason, delirium, medication, etc. It can be a source of complication, for the patient, and equipment pullout. International recommendations state that the agitation should be taken care of with standardized protocols to improve patient care.
Data regarding patient characteristics and evaluation criterion will be collected automatically with the unit software (CCC, General Electrics) in specific file. Care and health teams enter the data systematically following the usual protocol. First Step : Follow-up and collection of data of patients included. Agitation evaluation with RASS scale, pain evaluation with BPS or NPRS. Second Step: Team training to delirium evaluation scale (CAM-ICU) and to the use of care algorithm. Third Step: Follow-up and collection of data of patients included. Use of care algorithm by doctors, nurses and back up training nurse to ensure daily information to health professionals of the care unit. Concomitant Step: Post discharge from care unit medical appointment to evaluate anxiety symptoms (HAD scale) and quality of life (SF-12) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03110900 -
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
|
Phase 4 | |
| Completed |
NCT05272501 -
CAlming Touch for People With Agitation or Other Behavioural Symptoms of DEMentia - A Randomized Feasibility Trial
|
N/A | |
| Completed |
NCT06041646 -
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
|
Phase 4 | |
| Recruiting |
NCT06217146 -
A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.
|
N/A | |
| Recruiting |
NCT05543681 -
IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's
|
Phase 2 | |
| Recruiting |
NCT03513549 -
Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
|
||
| Active, not recruiting |
NCT05658510 -
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
|
Phase 3 | |
| Not yet recruiting |
NCT05612711 -
Dronabinol for Agitation in Dementia Crossover Trial
|
Phase 2 | |
| Recruiting |
NCT04957238 -
Physical Restraints in Intensive Care Unit Patients
|
N/A | |
| Completed |
NCT03208452 -
The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation
|
Phase 4 | |
| Terminated |
NCT03899506 -
Olanzapine Versus Midazolam for Agitation
|
||
| Completed |
NCT03211897 -
Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation
|
N/A | |
| Recruiting |
NCT05783505 -
A Multicomponent Intervention Program to Prevent and Reduce ICU Agitation and Physical Restraint Use
|
N/A | |
| Completed |
NCT03226522 -
Addressing Dementia Via Agitation-Centered Evaluation
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03926520 -
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)
|
N/A | |
| Recruiting |
NCT04075435 -
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
|
Early Phase 1 | |
| Completed |
NCT04276883 -
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
|
Phase 3 | |
| Completed |
NCT04797715 -
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
|
Phase 3 | |
| Completed |
NCT04251910 -
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05765162 -
Safe Brain Initiative, Operationalizing Precision Anaesthesia
|